Vancouver, BC, December 23, 2022--Achieve Life Sciences, Inc. , a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the mesylate salt formulation of cytisinicline and the process for its development.
|